CRDF
Cardiff Oncology, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.89
−1.71%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$0.92
From 52W high−72.41%
Volume427157.00
Market cap$68.90M
P/E (TTM)—
P/S (TTM)135.6x
Div yield—
Key dataOct 19, 2026
Open
$0.92
From 52W high
−72.41%
Volume
427157.00
Market cap
$68.90M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.9x
P/E (TTM)
—
RSI (14)
29.4
MomentumView details →
1D Return
−1.71%
YTD Return
−67.91%
SummaryUpdated Jun 1, 2026
Cardiff Oncology, Inc. (NASDAQ:CRDF) is a clinical-stage biotechnology company founded in 1999 and headquartered in San Diego, California. Originally incorporated as Trovagene, Inc., the company changed its name to Cardiff Oncology in May 2012 to reflect its focused mission on developing innovative cancer treatments. The company went public in 2004 and has since dedicated itself to advancing novel therapeutic approaches for cancer patients, with a particular emphasis on targeting specific molecular pathways that drive tumor growth and resistance to existing treatments.
Similar companies
Latest newsMore news →
Cardiff Oncology and Nerviano Medical Sciences signed a confidential settlement agreement on September 14, 2026 to dismiss their litigation with prejudice and exchange mutual releases, with no monetary payment or admission of liability.35d agoCardiff Oncology and Nerviano Medical Sciences amended their 2017 exclusive license agreement.35d agoCardiff Oncology presented positive Phase 2 CRDF-004 data at ASCO supporting advancement of 30 mg onvansertib plus FOLFIRI/bevacizumab into a planned registrational program for first-line RAS-mutated metastatic colorectal cancer.69d ago